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Background
Threshold countries like South Africa provide cardiac
surgery to a largely indigent population with rheumatic
heart disease. Although repairs are a preferred treatment
modality many rheumatic mitral valves can only be
replaced. In view of significantly improved primary health
care and broad access of the indigent population to com-
munication technology we revisited the efficacy of mitral
valve replacement (MVR) at the interface of the developing
and developed world.
Methods
A cohort of 280 patients (mean age 40.7±13.7y/range
12-80y/median 41y; 76.4% female) with rheumatic heart
disease (21% MR; 11% MS; 68% mixed) undergoing mitral
valve replacement (MVR) (88.2% mechanical versus 11.8%
tissue valves) was analyzed.
Results
Follow-up for the entire cohort was 94% complete (med-
ian follow-up period 3.5 years). Actuarial 5-year freedom
from valve related reoperation/death was 81.5±2.9%/96.7
±1.3% in the mechanical and 81.8±6.7% /100±0% in the
tissue valve group (p = 0.562/0.970). There was no signifi-
cant difference in freedom from death or reoperation irre-
spective of whether INR tests were performed or not. In
the mechanical group, partition modeling demonstrated a
significant difference with respect to freedom from death
(95.3±3.2% versus 82.9±4.1% %; p = 0.013) but not with
respect to freedom from reoperation (98.2±1.8% versus
96.2±3.8%; p = 0.329) between patients divided by an INR
cut point of 34% of tests falling within the therapeutic
range. Compared to the tissue valve group, the mechanical
group with poor INR control was statistically equivalent
with respect to survival and reoperation rate.
Conclusion
Overall circumstances for patients with rheumatic heart
disease needing mitral valve replacement in a developing
country have become conducive for the use of mechani-
cal prostheses. Yet, the remaining inferior outcome in
patients with suboptimal INR control highlights the
need for alternative anticoagulation agents that require
less stringent dosing.
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